The healthcare sector is one of the best-performing sectors in the S&P 500 over the past month, with a gain of around 6%. But while that rebound has been led by a handful of mega-cap Big Pharma companies, it has also been reflected in the performances of smaller firms
One of those is mid-cap Hims & Hers Health NYSE: HIMS, the telehealth platform that provides direct-to-consumer (D2C) personal care products and virtual medical services
Get Hims & Hers Health alerts:
Over the past 30 days, HIMS is up more than 45%, which has brought the stock’s year-to-date (YTD) gain to nearly 20%. After a run like that, the stock may be due for a short-term breather. But according to healthcare industry experts, a looming catalyst could have an outsized benefit on Hims & Hers in 2027 and beyond, which is setting the stock up for a buying opportunity on its next pullback
The GLP-1 Craze Is Pushing Up Employers’ Healthcare Plan Costs
Hims & Hers Health Today
HIMS
Hims & Hers Health
$38.34+1.54 (+4.18%)As of 03:59 PM Eastern This is a fair market value price provided by Massive. Learn more.
52-Week Range
$13.74▼
$70.43
Price Target
$30.63
Add to Watchlist
As the cost of weight-loss drugs continues to climb, Reuters recently reported that some employers are planning to drop coverage for GLP-1 treatments, including Wegovy, Ozempic, Zepbound, Mounjaro, and Foundayo—products manufactured by Novo Nordisk NYSE: NVO and Eli Lilly NYSE: LLY
Ad InvestorPlace
You must do this before the OpenAI IPO
OpenAI – the company behind ChatGPT – has begun filing confidential paperwork for what could be the largest IPO in American history.nnBut in nearly every major tech IPO of the last 15 years, day-one buyers underperformed. A small group using a lesser-known pre-IPO strategy made as much as 3,900% instead. Senior Technology Analyst Luke Lango calls it the Pre-IPO Backdoor – and it’s opening again.
Get the full story and a free ticker you can invest in today
